RareMD
RareMD Inc. is a healthcare technology company focused on improving the diagnosis of rare diseases through its digital diagnostic tools, RareMDx™ and RareLook™. RareMDx™ is designed for medical professionals to generate rare disease-inclusive differential diagnoses by selecting patient signs and symptoms, leveraging a curated database of over 4,000 rare diseases and advanced algorithms combining human intelligence and artificial intelligence. RareLook™ is a layman-friendly version for patients, parents, and caregivers to create a science-backed second opinion and facilitate communication with physicians. The company operates a corporate social responsibility initiative providing free access to RareMDx™ in emerging countries in exchange for de-identified diagnostic data. RareMD's business model involves sponsorship by pharmaceutical companies marketing orphan drugs, who fund free access to medical professionals, thereby increasing diagnosis rates and enabling treatment and clinical trial enrollment. The platform supports over 4,000 rare diseases, 7,360 medical ontology terms, and connects users to 45 Rare Disease Centers of Excellence worldwide. RareMD is positioned as a critical tool to shorten the diagnostic odyssey for rare disease patients, improve clinical outcomes, and accelerate orphan drug development and market access.
RareMD
RareMD Inc. is a healthcare technology company focused on improving the diagnosis of rare diseases through its digital diagnostic tools, RareMDx™ and RareLook™. RareMDx™ is designed for medical professionals to generate rare disease-inclusive differential diagnoses by selecting patient signs and symptoms, leveraging a curated database of over 4,000 rare diseases and advanced algorithms combining human intelligence and artificial intelligence. RareLook™ is a layman-friendly version for patients, parents, and caregivers to create a science-backed second opinion and facilitate communication with physicians. The company operates a corporate social responsibility initiative providing free access to RareMDx™ in emerging countries in exchange for de-identified diagnostic data. RareMD's business model involves sponsorship by pharmaceutical companies marketing orphan drugs, who fund free access to medical professionals, thereby increasing diagnosis rates and enabling treatment and clinical trial enrollment. The platform supports over 4,000 rare diseases, 7,360 medical ontology terms, and connects users to 45 Rare Disease Centers of Excellence worldwide. RareMD is positioned as a critical tool to shorten the diagnostic odyssey for rare disease patients, improve clinical outcomes, and accelerate orphan drug development and market access.